Cusatuzumab
Newly Diagnosed Acute Myeloid Leukemia (AML) ineligible for intensive treatment
Phase 1/2Active
Key Facts
Indication
Newly Diagnosed Acute Myeloid Leukemia (AML) ineligible for intensive treatment
Phase
Phase 1/2
Status
Active
Company
About OncoVerity
OncoVerity is a private, clinical-stage biotech leveraging a computational bioinformatics platform to identify and develop novel therapies for cancer, with a primary focus on acute myeloid leukemia (AML). The company's lead asset is cusatuzumab, an anti-CD70 monoclonal antibody in development for newly diagnosed AML, which has progressed into clinical trials and recently secured extended Series A funding. By integrating multi-omics data and a team with deep clinical and industry experience, OncoVerity aims to deliver personalized, transformative treatments for patients with high unmet need.
View full company profile